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Abstract
Background. This study provides a summary of the 2010 European Renal Association–European
Dialysis and Transplant Association (ERA–EDTA) Registry Annual Report (available at www.era-
edta-reg.org).
Methods. This report includes data on renal replacement therapy (RRT) using data from the na-
tional and regional renal registries in 29 countries in Europe and bordering the Mediterranean
Sea. Individual patient data were received from 27 registries, whereas 18 registries contributed
data in aggregated form. We present incidence and prevalence of RRT, transplant rates, survival
probabilities and expected remaining lifetimes. The latter two are solely based on individual
patient records.
Results. In 2010, the overall incidence rate of RRT for end-stage renal disease (ESRD) among all
registries reporting to the ERA–EDTA Registry was 123 per million population (pmp) (n = 91 798).
The highest incidence rate was reported by Turkey (252 pmp) and the lowest reported by Monte-
negro (21 pmp). The overall prevalence of RRT for ESRD at 31 December 2010 among all registries
reporting to the ERA–EDTA Registry was 741 pmp (n = 551 005). The prevalence varied from 124
pmp in Ukraine to 1580 pmp in Portugal. The overall number of renal transplantations performed
in 2010 among all registries was 29.2 pmp (n = 21 740). The highest overall transplant rate was
reported from Spain, Cantabria (73 pmp), whereas the highest transplant rate for living donor
kidneys was reported from the Netherlands (28 pmp). For patients who started RRT between
2001 and 2005, the unadjusted 5-year patient survival on RRT was 46.2% [95% conﬁdence
interval (CI) 46.0–46.3], and on dialysis 38.6% (95% CI 38.5–38.8). The unadjusted 5-year patient
survival after the ﬁrst renal transplantation performed between 2001 and 2005 was 86.6%
(95% CI 86.1–87.1) for deceased donor kidneys and 94.1% (95% CI 93.4–94.8) for living donor
kidneys.
Introduction
The summary of the 2010 ERA–EDTA (European Renal
Association–European Dialysis and Transplant Association)
Registry Report includes data on renal replacement therapy
(RRT) using 52 datasets from the national and regional renal
registries of 29 countries in Europe and bordering the Medi-
terranean Sea (Figure 1). Datasets with individual patient
data for analysis were received from 27 national and
regional registries in 14 countries, whereas 18 national regis-
tries from 18 countries contributed data in aggregated form.
Fig. 1. Incidence of RRT pmp at Day 1, 2010 among all national and regional renal registries in 29 countries reporting to the ERA-EDTA Registry in 2010.
B&H, Bosnia–Herzegovina; FYROM, Former Yugoslav Republic of Macedonia; ME, Montenegro. The incidence data for the Czech Republic, Italy, Slovakia
and Turkey include dialysis patients only.
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Fig. 2. Incidence of RRT pmp at Day 1 in 2010, unadjusted and standardized to the age and gender distribution of the EU27 population, and the mean
and median age (years) at RRT initiation. Figures include data from renal registries providing individual patient data (left ﬁgure) and aggregated data
(right ﬁgure). The aggregated data from the Czech Republic, Italy, Slovakia and Turkey include dialysis patients only.
Table 1. Incidence of RRT at Day 1 by age group, as counts (N) and pmarp, unadjusted
Country/region providing individual patient data
0–19 years 20–44 years 45–64 years 65–74 years 75+ years
N (pmarp) N (pmarp) N (pmarp) N (pmarp) N (pmarp)
Austria 11 (6.3) 111 (38.2) 355 (156.5) 358 (444.3) 327 (486.4)
Belgium
Dutch-speakinga 92 (45.5) 288 (166.0) 292 (507.0) 554 (975.0)
French-speakinga 76 (48.1) 275 (229.4) 195 (560.5) 339 (893.5)
Denmark 9 (6.6) 83 (45.9) 233 (155.0) 170 (319.6) 178 (456.1)
Finland 11 (9.0) 49 (29.2) 163 (105.9) 131 (265.0) 83 (192.4)
France (20 of 26 regions) 88 (7.8) 623 (41.8) 1859 (149.4) 1580 (412.7) 2841 (660.8)
Greece 20 (9.1) 154 (38.5) 532 (180.2) 555 (501.4) 893 (848.4)
Iceland 1 (11.1) 4 (35.6) 8 (103.8) 9 (448.1) 11 (593.4)
Italy (8 of 20 regions) 19 (6.7) 185 (34.9) 547 (129.0) 585 (367.4) 817 (503.1)
Norway 7 (5.6) 88 (52.8) 143 (114.7) 131 (344.6) 140 (397.4)
Romania 34 (7.6) 426 (50.2) 1164 (220.6) 686 (378.7) 356 (257.0)
Spain
Andalusia 14 (7.6) 148 (45.5) 319 (157.3) 239 (365.3) 269 (439.6)
Aragon 3 (12.3) 20 (40.8) 50 (144.9) 50 (426.4) 43 (286.3)
Asturias 2 (13.0) 19 (50.6) 36 (113.9) 35 (335.8) 45 (333.9)
Basque country 4 (10.6) 30 (38.8) 85 (139.7) 67 (331.5) 49 (222.6)
Canary Islands 1 (2.4) 42 (48.0) 125 (233.0) 73 (454.7) 90 (702.0)
Cantabriaa 6 (27.6) 26 (159.9) 26 (529.3) 18 (294.0)
Castile and Leóna 31 (35.4) 99 (144.1) 62 (248.9) 106 (319.3)
Castile-La Manchaa 29 (35.9) 68 (138.8) 67 (406.8) 61 (296.2)
Catalonia 9 (6.0) 101 (34.4) 290 (157.1) 231 (386.3) 324 (505.3)
Extremadura 1 (4.5) 19 (48.0) 49 (176.9) 44 (450.9) 36 (313.6)
Galicia 2 (4.5) 53 (53.6) 117 (157.5) 94 (325.7) 118 (351.2)
Valencian region 9 (8.9) 82 (41.6) 224 (176.0) 173 (386.7) 220 (538.6)
Sweden 29 (13.3) 139 (45.3) 348 (144.4) 299 (326.8) 320 (400.4)
The Netherlands 38 (9.7) 232 (42.4) 613 (131.7) 535 (379.1) 542 (469.1)
UK, All countriesa 1073 (50.4) 2236 (140.7) 1608 (297.8) 1693 (345.2)
Englanda 907 (50.5) 1922 (145.2) 1317 (293.5) 1400 (339.9)
Northern Irelanda 22 (35.1) 53 (122.6) 45 (314.2) 55 (468.9)
Scotland 7 (6.0) 92 (52.6) 161 (113.4) 134 (282.8) 125 (308.1)
Walesa 52 (55.3) 100 (125.3) 112 (379.0) 113 (430.1)
All countries 319 (8.0) 3915 (44.4) 10 252 (153.7) 8295 (371.2) 10 473 (490.0)
aPatients <20 years of age are not reported.
The 2010 ERA–EDTA Registry Annual Report 107
 at M
edical and H
ealth Inform
ation Center on A
ugust 12, 2014
http://ckj.oxfordjournals.org/
D
ow
nloaded from
 
Table 2. Incidence of RRT at Day 1 over the period 2009–2010 among patients aged 0–19, by age group, as counts (N) and pmarp, unadjusted
Cohort
0–4 years 5–9 years 10–14 years 15–19 years 0–19 years
N (pmarp) N (pmarp) N (pmarp) N (pmarp) N (pmarp)
All countries 143 (8.0) 87 (4.9) 146 (8.3) 257 (13.5) 633 (8.8)
Table 3. Incidence of RRT at Day 1 by PRD for countries/regions providing individual patient data and for countries/regions providing aggregated data,
as counts (N) and pmp, unadjusted
Country
GN
DM
HT/RVD Other Unkn/MissType 1 Type II Both
N (pmp) N (pmp) N (pmp) N (pmp) N (pmp) N (pmp) N (pmp)
Regions providing individual patient data
Austria 123 (14.7) 34 (4.1) 316 (37.7) 350 (41.7) 238 (28.4) 296 (35.3) 155 (18.5)
Belgium
Dutch-speakinga 101 (16.1) 34 (5.4) 223 (35.5) 257 (40.9) 203 (32.3) 563 (89.7) 102 (16.2)
French-speakinga 90 (19.5) 18 (3.9) 165 (35.7) 183 (39.6) 231 (50.0) 319 (69.1) 62 (13.4)
Denmark 80 (14.3) 61 (10.9) 94 (16.8) 155 (27.7) 91 (16.3) 176 (31.5) 171 (30.5)
Finland 48 (8.9) 53 (9.9) 98 (18.3) 151 (28.2) 25 (4.6) 136 (25.3) 77 (14.4)
France (20 of 26 regions) 792 (16.9) 1461 (31.2) 1766 (37.8) 1910 (40.9) 1062 (22.7)
Greece 160 (14.1) 32 (2.8) 597 (52.8) 629 (55.6) 290 (25.7) 396 (35.0) 679 (60.0)
Iceland 6 (18.9) 1 (3.1) 4 (12.6) 5 (15.7) 10 (31.5) 7 (22.0) 5 (15.7)
Italy (8 of 20 regions) 225 (14.4) 409 (26.2) 512 (32.8) 513 (32.9) 494 (31.7)
Norway 80 (16.4) 35 (7.2) 52 (10.6) 87 (17.8) 188 (38.4) 139 (28.4) 15 (3.1)
Romania 389 (18.1) 379 (17.7) 173 (8.0) 689 (32.1) 1036 (48.3)
Spain
Andalusia 119 (14.2) 225 (26.8) 167 (19.9) 264 (31.4) 214 (25.5)
Aragon 20 (14.9) 5 (3.7) 36 (26.7) 41 (30.4) 26 (19.3) 43 (32.0) 36 (26.7)
Asturias 7 (6.5) 10 (9.2) 20 (18.4) 30 (27.7) 23 (21.2) 29 (26.7) 48 (44.3)
Basque country 42 (19.3) 15 (6.9) 24 (11.0) 39 (17.9) 41 (18.8) 68 (31.1) 45 (20.6)
Canary Islands 154 (72.6) 177 (83.4)
Cantabriaa 19 (32.1) 2 (3.4) 14 (23.6) 16 (27.0) 25 (42.2) 14 (23.6) 2 (3.4)
Castile and Leóna 36 (14.1) 16 (6.3) 67 (26.2) 83 (32.4) 57 (22.2) 76 (29.7) 46 (18.0)
Castile-La Manchaa 30 (14.2) 58 (27.5) 19 (9.0) 61 (29.0) 57 (27.1)
Catalonia 98 (13.0) 25 (3.3) 190 (25.3) 217 (28.9) 144 (19.2) 229 (30.5) 267 (35.5)
Extremadura 14 (12.6) 49 (44.2) 13 (11.7) 31 (27.9) 42 (37.9)
Galicia 42 (15.0) 20 (7.2) 79 (28.2) 99 (35.4) 48 (17.2) 88 (31.4) 107 (38.3)
Valencian region 81 (15.8) 129 (25.2) 174 (34.0) 165 (32.3) 159 (31.1)
Sweden 149 (15.9) 100 (10.7) 170 (18.1) 270 (28.8) 209 (22.3) 290 (30.9) 217 (23.1)
The Netherlands 150 (9.0) 56 (3.4) 221 (13.3) 277 (16.7) 452 (27.2) 477 (28.7) 604 (36.4)
UK, All countriesa 797 (12.8) 1396 (22.4) 692 (11.1) 1879 (30.2) 1846 (29.7)
Englanda 641 (12.3) 1135 (21.7) 551 (10.5) 1572 (30.1) 1647 (31.5)
Northern Irelanda 22 (12.2) 46 (25.6) 19 (10.6) 58 (32.2) 30 (16.7)
Scotland 74 (14.2) 121 (23.2) 72 (13.8) 162 (31.0) 90 (17.3)
Walesa 60 (20.0) 94 (31.3) 51 (17.0) 92 (30.6) 80 (26.6)
All countries 3698 (14.5) 2627 (10.3) 3202 (12.5) 7149 (28.0) 5818 (22.8) 8863 (34.6) 7726 (30.2)
Regions providing aggregated data
Bosnia and Herzegovina 51 (14.5) 27 (7.7) 97 (27.7) 124 (35.3) 82 (23.4) 184 (52.4) 69 (19.7)
Croatia 73 (16.5) 168 (37.9) 114 (25.7) 172 (38.8) 95 (21.4)
Estonia 11 (8.2) 15 (11.2) 6 (4.5) 21 (15.7) 28 (20.9) 40 (29.9) 0 (0)
France (23 of 26 regions)b 1018 (16.1) 2037 (32.2) 2282 (36.1) 2490 (39.4) 1612 (25.5)
FYR of Macedonia 24 (11.9) 4 (2.0) 45 (22.3) 49 (24.2) 83 (41.1) 52 (25.7) 41 (20.3)
Israel 92 (12.2) 460 (60.3) 175 (23.0) 635 (83.3) 212 (27.8) 216 (28.3) 268 (35.0)
Italy (14 of 20 regions)c 919 (24.0) 1252 (32.6) 1314 (34.2) 1085 (28.3) 1597 (41.4)
Latvia 36 (16.2) 5 (2.2) 33 (14.8) 38 (17.0) 46 (20.6) 125 (56.1) 24 (10.8)
Montenegro 5 (8.1) 4 (6.5) 0 (0) 4 (6.5) 2 (3.2) 1 (1.6) 1 (1.6)
Poland 915 (25.3) 1189 (32.8) 775 (21.3) 625 (17.3) 1670 (46.0)
Portugald 207 (19.5) 793 (74.7) 378 (35.6) 582 (54.6) 559 (52.6)
Russia 1887 (13.3) 431 (3.0) 454 (3.2) 885 (6.2) 487 (3.4) 2061 (14.5) 286 (2.0)
Serbia 138 (18.3) 98 (13.0) 239 (31.6) 337 (44.6) 371 (49.3) 475 (63.2) 99 (13.2)
Slovakiac 89 (16.9) 329 (62.6) 110 (20.9) 339 (64.1) 15 (2.8)
Spain (18 of 19 regions) 640 (14.0) 1356 (29.8) 788 (17.3) 1516 (33.3) 1218 (26.7)
Turkeyc 1086 (17.7) 993 (16.2) 4001 (65.0) 4994 (81.1) 4218 (68.7) 3086 (50.2) 2125 (34.4)
Ukraine 371 (8.2) 229 (5.2) 65 (1.4) 334 (7.3) 42 (0.9)
All countries 7562 (15.8) 2037 (4.3) 5050 (10.6) 14 440 (30.3) 11 355 (23.8) 13 383 (28.0) 9721 (20.4)
GN, glomerulonephritis/sclerosis; DM, diabetes mellitus; HT/RVD, hypertension/renal vascular disease; Unkn/Miss, unknown/missing.
aPatients <20 years of age are not reported.
bThe type of diabetes is given by the comorbidity and not by the cause of renal failure.
cData include dialysis patients only.
dRenal vascular disease is not reported separately, but is included in the category Other.
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The incidence and prevalence data as well as trans-
plant rates were based on the data from countries and
regions that provided individual patient data or aggre-
gated data. Survival analysis and the calculation of ex-
pected remaining lifetimes were solely based on
individual patient records. More detailed data than those
presented in the paper were published in the full 2010
ERA–EDTA Registry Annual Report [1] which is also avail-
able on www.era-edta-reg.org.
The incidence of RRT for end-stage renal disease
In 2010, the overall number of patients starting RRT for
end-stage renal disease (ESRD) among all registries
reporting to the ERA–EDTA Registry was 91 798. The total
population covered by these registries was 743.7 million
resulting in an unadjusted incidence rate of 123 per
million population (pmp). The highest unadjusted inci-
dence rates were reported from Turkey (252 pmp), Portu-
gal (237 pmp) and the Czech Republic (198 pmp). The
incidence rate standardized for the EU 27 population was
also highest in Turkey (411 pmp). Unadjusted incidence
rates <50 pmp were reported by Montenegro (21 pmp),
Ukraine (23 pmp) and Russia (40 pmp). The mean age
was 64.8 years for countries/regions providing individual
patient data and 57.6 years for countries/regions provid-
ing aggregated data. It varied across countries ranging
from 48.9 years in Russia to 69.8 years in Belgium
(Dutch-speaking) (Figure 2).
Table 4. Incidence of RRT at Day 91 by treatment modality for countries/regions providing individual patient data and for countries/regions providing
aggregated data, as counts (N) and pmp, unadjusted
Country
All HD PD Tx Unkn/Miss
N (pmp) N (pmp) N (pmp) N (pmp) N (pmp)
Regions providing individual patient data
Austria 1034 (123.2) 884 (105.4) 106 (12.6) 44 (5.2) 0 (0)
Belgium
Dutch-speakinga 1097 (174.7) 967 (154.0) 116 (18.5) 14 (2.2) 0 (0)
French-speakinga 819 (177.4) 699 (151.4) 97 (21.0) 23 (5.0) 0 (0)
Denmark 622 (111.0) 391 (69.8) 195 (34.8) 35 (6.2) 1 (0.2)
Finland 426 (79.4) 313 (58.4) 111 (20.7) 2 (0.4) 0 (0)
France (20 of 26 regions) 6487 (138.7) 5388 (115.2) 806 (17.2) 281 (6.0) 12 (0.2)
Greece 1923 (170.1) 1755 (155.2) 155 (13.7) 13 (1.1) 0 (0)
Iceland 32 (100.6) 23 (72.3) 7 (22.0) 2 (6.3) 0 (0)
Italy (8 of 20 regions)b 1982 (127.2) 1670 (107.1) 303 (19.5) 9 (0.6) 0 (0)
Norway 482 (98.6) 315 (64.4) 98 (20.0) 69 (14.1) 0 (0)
Romania 2206 (102.9) 1968 (91.8) 214 (10.0) 24 (1.1) 0 (0)
Spain
Andalusia 951 (113.2) 818 (97.4) 101 (12.0) 32 (3.8) 0 (0)
Aragon 158 (117.3) 137 (101.7) 18 (13.4) 3 (2.2) 0 (0)
Asturiasb 121 (111.6) 93 (86.1) 18 (16.3) 10 (9.2) 0 (0)
Basque country 220 (100.8) 175 (80.2) 40 (18.3) 5 (2.3) 0 (0)
Canary Islandsa 308 (145.3) 269 (126.9) 38 (17.7) 1 (0.6) 0 (0)
Cantabriaa 71 (119.8) 45 (75.9) 20 (33.7) 6 (10.1) 0 (0)
Castile and Leóna 292 (114.1) 233 (91.1) 53 (20.7) 6 (2.3) 0 (0)
Castile-La Manchaa 225 (106.8) 186 (88.3) 35 (16.6) 4 (1.9) 0 (0)
Cataloniab 911 (121.3) 722 (96.2) 119 (15.9) 69 (9.2) 0 (0)
Extremadurab 140 (126.0) 117 (105.9) 21 (18.9) 1 (1.2) 0 (0)
Galiciab 372 (133.0) 268 (96.0) 90 (32.1) 14 (5.0) 0 (0)
Valencian region 699 (136.7) 591 (115.6) 92 (18.0) 16 (3.1) 0 (0)
Sweden 1034 (110.3) 625 (66.6) 326 (34.8) 83 (8.9) 0 (0)
The Netherlands 1794 (108.0) 1211 (72.9) 365 (22.0) 218 (13.1) 0 (0)
UK, All countriesa,b 6203 (99.6) 4483 (72.0) 1203 (19.3) 509 (8.2) 9 (0.1)
Englanda,b 5206 (99.7) 3704 (70.9) 1031 (19.7) 467 (8.9) 3 (0.1)
Northern Ireland a,b 166 (92.1) 145 (80.4) 13 (7.0) 8 (4.6) 0 (0)
Scotland 485 (92.9) 378 (72.4) 88 (16.9) 15 (2.9) 4 (0.8)
Walesa,b 352 (117.0) 260 (86.4) 71 (23.6) 20 (6.5) 1 (0.4)
All countries 30 615 (119.7) 24 350 (95.2) 4747 (18.6) 1494 (5.8) 21 (0.1)
Regions providing aggregated data
Bosnia and Herzegovina 439 (125.1) 418 (119.2) 20 (5.7) 1 (0.3) 0 (0)
Croatia 557 (125.5) 501 (112.9) 49 (11.0) 7 (1.6) 0 (0)
Czech Republicc 1579 (149.9) 1493 (141.7) 86 (8.2) 0 (0)
Estonia 98 (73.1) 72 (53.7) 25 (18.7) 1 (0.7) 0 (0)
France (23 of 26 regions) 8230 (130.1) 6925 (109.4) 816 (12.9) 484 (7.6) 5 (0.1)
FYR of Macedonia 202 (99.9) 198 (97.9) 2 (1.0) 2 (1.0) 0 (0)
Israel 1340 (175.8) 1191 (156.2) 113 (14.8) 36 (4.7) 0 (0)
Italy (14 of 20 regions)c 5850 (152.2) 5076 (132.1) 584 (15.2) 190 (4.9)
Latvia 240 (107.7) 204 (91.5) 36 (16.2) 0 (0) 0 (0)
Montenegro 7 (11.3) 4 (6.5) 1 (1.6) 2 (3.2) 0 (0)
Serbia 1005 (133.5) 873 (116.0) 120 (15.9) 12 (1.6) 0 (0)
Slovakiac 718 (136.2) 697 (132.2) 21 (4.0) 0 (0)
Turkeyc 13 194 (214.5) 11 932 (194.0) 1262 (20.5) 0 (0)
All countries 33 459 (160.6) 29 584 (142.0) 3135 (15.0) 545 (5.9) 195 (0.9)
HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; Unkn/Miss, unknown/missing.
aPatients <20 years of age are not reported.
bThe incident counts at Day 91 are estimated.
cData include dialysis patients only.
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Table 1 reports the unadjusted incidence rate of RRT
per million age-related population (pmarp) at Day 1 by
age group. Especially in the highest age category (75+
years at the start of RRT), there is a substantial variation
in incidence rates, ranging from 192 pmarp in Finland to
975 pmarp in Dutch-speaking Belgium.
For children we performed a separate analysis includ-
ing data from a limited number of registries: Austria,
Denmark, Finland, France, Greece, Iceland, Norway,
Romania, Spain (Andalusia), Spain (Aragon), Spain (Astur-
ias), Spain (Basque country), Spain (Canary Islands),
Spain (Catalonia), Spain (Extremadura), Spain (Galicia),
Spain (Valencian region), Sweden, the Netherlands and
UK (Scotland) (Table 2). As numbers of children starting
RRT were low, we present averages for 2009–10. Please
visit www.espn-reg.org for a more detailed overview of
paediatric RRT data in Europe.
Table 3 shows that the number of patients pmp start-
ing RRT in 2010 for ESRD due to diabetes mellitus varied
across countries from 5.2 pmp in Ukraine to 83.3 pmp in
Israel. For those renal registries making the distinction
between diabetes mellitus type I and II, the number of
patients pmp starting RRT for ESRD due to diabetes melli-
tus type I varied from 2 pmp in the FYR of Macedonia to
60 pmp in Israel and for that due to diabetes mellitus
type II from 3 pmp in Russia to 65 pmp in Turkey.
The incidence of the different treatment modalities
[haemodialysis (HD), peritoneal dialysis (PD) and trans-
plantation (Tx)] in 2010 was measured as the number of
patients pmp on a treatment modality at Day 91 of RRT
(Table 4). Whereas the incidence rates of HD were highest
in Turkey (194 pmp), Israel (156 pmp) and Greece (155
pmp), the incidence rates of PD were highest in Sweden
and Denmark (both 35 pmp), and Spain, Cantabria (34
pmp). The highest incidence rates of patients living on a
functioning graft at Day 91 of RRT were observed in
Norway (14 pmp), the Netherlands (13 pmp) and Spain,
Cantabria (10 pmp).
The prevalence of RRT for ESRD
The overall prevalence count at 31 December 2010
among all registries reporting to the ERA–EDTA Registry
was 551 005, corresponding to a prevalence of 741 pmp.
Figure 3 shows that the unadjusted prevalence of RRT
pmp was highest in Portugal (1580 pmp), Belgium
(French-speaking) (1237 pmp) and Spain, Catalonia
(1188 pmp). The lowest unadjusted prevalence was re-
ported by Ukraine (124 pmp) and Russia (186 pmp).
Figure 3 also shows the prevalence of RRT standardized
for the EU 27 population. Furthermore, the mean age of
the prevalent patients on RRT at 31 December 2010
ranged from 47.5 years in Russia to 67.4 years in Italy,
whereas the overall mean age was 60.2 years among the
countries providing individual patient data and 55.0 years
among the countries providing aggregated data
(Figure 3). Table 5 shows the unadjusted prevalence of
RRT pmarp at 31 December 2010 by age group. Especially
in the highest age category (75+ years at the start of
RRT), there is a remarkable variation in prevalence,
Fig. 3. Prevalence of RRT pmp at 31 December 2010, unadjusted and standardized to the age and gender distribution of the EU27 population, and the
mean and median age (years). Figures include data from renal registries providing individual patient data (left ﬁgure) and aggregated data (right
ﬁgure). The aggregated data from Israel, Italy and Slovakia include dialysis patients only. In Italy, the prevalence of RRT is underestimated by ∼11%,
due to an estimated 25–30% under-reporting of patients living on a functioning graft, and in Romania, the prevalence of RRT is underestimated by
∼3%, due to an estimated 30% under-reporting of patients living on a functioning graft.
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ranging from 952 pmp in Romania to 3902 pmp in Dutch-
speaking Belgium. Table 6 shows the prevalence for the
age group 0–19 years, averaged for 2009 and 2010.
As presented in Table 7, the prevalence of HD at 31 De-
cember 2010 was highest in Portugal (955 pmp) and
Greece (800 pmp) and lowest in Ukraine (92 pmp) and
Russia (132 pmp). The prevalence of PD was highest in
Spain, Galicia (99 pmp) and Denmark (98 pmp), whereas
the lowest prevalence of this treatment was reported in
Russia (12 pmp) and FYR of Macedonia (13 pmp). Finally,
the prevalence of patients living on a functioning graft
was highest in Spain, the Basque country (623 pmp) and
Spain, Catalonia (613 pmp).
Renal transplants
The overall number of renal transplantations performed in
2010 among all registries reporting to the ERA–EDTA
Registry was 21 740 (29.2 pmp). Of these, 14 261 (19.2
pmp) renal transplantations were performed with a
kidney obtained from a deceased donor, 4312 (5.8 pmp)
with a kidney from a living donor and for 6137 (4.3 pmp)
transplantations the type of donor was unknown. Figure 4
shows that the highest overall transplant rates were re-
ported from Spain, Cantabria (73 pmp), Spain, Catalonia
(62 pmp), and Spain, Basque country (56 pmp). Countries
with the highest transplant rates with living donor kidneys
included the Netherlands (28 pmp), UK, Northern Ireland
(23 pmp), Sweden (18 pmp) and Denmark (18 pmp).
Patient and graft survival
Survival analysis used the data from 19 registries in 12
countries that provided individual patient records for the
period from 2001 to 2008. Four Spanish regions were also
included in the analyses based on the cohort 2004–08
Table 5. Prevalence of RRT on 31 December 2010 by age group, as counts (N) and pmarp, unadjusted
Country/region providing individual patient data
0–19 years 20–44 years 45–64 years 65–74 years 75+ years
N (pmarp) N (pmarp) N (pmarp) N (pmarp) N (pmarp)
Austria 102 (58.7) 1322 (455.1) 3551 (1565.2) 2025 (2513.1) 1355 (2015.7)
Belgium
Dutch-speakinga 846 (418.8) 2580 (1487.0) 1679 (2915.1) 2217 (3901.6)
French-speakinga 811 (513.8) 2188 (1825.5) 1239 (3561.4) 1474 (3885.2)
Denmark 93 (67.9) 997 (551.1) 1930 (1283.5) 1019 (1915.5) 706 (1809.2)
Finland 123 (100.7) 684 (408.0) 1945 (1263.3) 961 (1943.7) 529 (1226.5)
France (20 of 26 regions) 507 (45.0) 7686 (515.1) 18 890 (1518.6) 9929 (2593.4) 12 336 (2869.3)
Greece 108 (49.2) 1723 (430.4) 4190 (1419.3) 3024 (2731.7) 3166 (3007.8)
Iceland 5 (55.5) 53 (472.1) 70 (908.2) 36 (1792.4) 26 (1402.7)
Italy (8 of 20 regions)b 96 (33.8) 2246 (424.1) 5853 (1380.5) 3945 (2477.8) 4455 (2743.2)
Norway 78 (62.8) 819 (491.3) 1735 (1391.2) 902 (2372.6) 661 (1876.3)
Romaniac 115 (25.7) 2552 (300.5) 5506 (1043.7) 2593 (1431.6) 1319 (952.4)
Spain
Andalusia 101 (54.6) 1665 (511.5) 3452 (1702.4) 1832 (2800.0) 1508 (2464.4)
Aragon 10 (41.1) 218 (444.2) 578 (1675.2) 307 (2618.0) 367 (2443.7)
Asturias 6 (39.0) 168 (447.3) 433 (1370.4) 225 (2158.9) 245 (1818.1)
Basque country 32 (84.8) 373 (482.3) 938 (1541.8) 546 (2701.5) 407 (1849.1)
Canary Islands 9 (21.3) 445 (509.1) 997 (1858.2) 550 (3425.9) 436 (3400.6)
Cantabriaa 84 (386.6) 228 (1402.5) 126 (2565.2) 96 (1567.9)
Castile and Leóna 368 (420.8) 1010 (1470.3) 544 (2184.1) 687 (2069.5)
Castile-La Manchaa 352 (435.6) 767 (1566.0) 471 (2859.8) 445 (2160.6)
Catalonia 91 (61.1) 1421 (483.7) 3318 (1797.5) 2042 (3415.2) 2056 (3206.3)
Extremadura 4 (17.9) 212 (536.1) 448 (1617.8) 225 (2305.8) 218 (1899.0)
Galicia 13 (29.5) 525 (531.1) 1206 (1623.1) 745 (2581.4) 671 (1997.1)
Valencian region 65 (64.4) 907 (459.7) 2161 (1697.8) 1346 (3008.5) 1299 (3180.0)
Sweden 159 (72.7) 1429 (465.7) 3570 (1481.3) 2018 (2205.9) 1349 (1687.9)
The Netherlands 260 (66.3) 2754 (503.1) 6358 (1366.2) 3386 (2399.2) 2625 (2272.1)
UK, All countriesa 11 654 (547.5) 21 481 (1351.9) 9917 (1836.7) 8035 (1638.1)
Englanda 9692 (539.3) 17 973 (1357.5) 8290 (1847.6) 6720 (1631.3)
Northern Irelanda 348 (555.9) 571 (1321.1) 312 (2178.8) 263 (2242.1)
Scotland 94 (80.0) 1080 (618.0) 1880 (1324.1) 786 (1658.6) 594 (1464.1)
Walesa 534 (567.9) 1057 (1324.4) 529 (1790.2) 458 (1743.4)
All countries 2071 (51.87) 42 314 (479.4) 95 383 (1429.2) 51 632 (2309.8) 48 688 (2277.5)
aPatients <20 years of age are not reported.
bThe overall prevalence of RRT is underestimated by ∼11% due to an estimated 25–30% under-reporting of patients living on a functioning graft.
cThe overall prevalence of RRT is underestimated by ∼3% due to an estimated 30% under-reporting of patients living on a functioning graft.
Table 6. Prevalence of RRT on 31 December 2010 among patients aged 0–19, by age group, as counts (N) and pmarp, unadjusted
Cohort
0–4 years 5–9 years 10–14 years 15–19 years 0–19 years
N (pmarp) N (pmarp) N (pmarp) N (pmarp) N (pmarp)
All countries 185 (19.9) 313 (34.1) 509 (55.8) 1019 (105.3) 2026 (54.4)
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because for these registries, complete data were avail-
able from 2002. In Table 8, we present the results of the
unadjusted and adjusted survival analyses for all
countries together. The adjusted analyses used ﬁxed
values for age, gender and distribution of primary renal
disease (PRD). The precise methodology of the survival
analyses is described in the Appendix.
To calculate the expected remaining lifetimes, we
used data from 19 national and regional renal registries
in 12 countries that provided individual patient records
from 2001 until 2010 (Table 9). The expected remaining
lifetimes for patients on RRT are much lower than for
the general population, whereas those of dialysis
patients are even more reduced than those of transplant
recipients. The size of the reduction does, however,
depend on the patient’s age category: the younger the
patient, the more his/her remaining lifetime in years will
be reduced.
Table 7. Prevalence of RRT on 31 December 2010 by treatment modality for countries/regions providing individual patient data/and for countries/
regions providing aggregated data, as counts (N) and per million population (pmp), unadjusted
Country
HD PD Tx Unkn/Miss
N (pmp) N (pmp) N (pmp) N (pmp)
Regions providing individual patient data
Austria 3872 (461.5) 384 (45.8) 4099 (488.6) 0 (0)
Belgium
Dutch-speakinga 3926 (625.2) 398 (63.4) 2998 (477.4) 0 (0)
French-speakinga 3091 (669.6) 292 (63.3) 2329 (504.5) 0 (0)
Denmark 2042 (364.4) 550 (98.1) 2130 (380.1) 23 (4.1)
Finland 1411 (263.1) 320 (59.7) 2511 (468.2) 0 (0)
France (20 of 26 regions) 25 744 (550.6) 2139 (45.7) 21 110 (451.5) 355 (7.6)
Greece 9048 (800.2) 755 (66.8) 2409 (213.0) 0 (0)
Iceland 60 (188.7) 12 (37.7) 118 (371.0) 0 (0)
Italy (8 of 20 regions)b 10 583 (678.9) 1208 (77.5) 4798 (307.8) 6 (0.4)
Norway 1000 (204.5) 220 (45.0) 2975 (608.5) 0 (0)
Romania 9707 (452.8) 1525 (71.1) 853 (39.8) 0 (0)
Spain
Andalusia 4102 (488.5) 361 (43.0) 4095 (487.6) 0 (0)
Aragon 636 (472.3) 39 (29.0) 804 (597.0) 1 (0.7)
Asturiasb 406 (374.4) 63 (58.1) 608 (560.7) 0 (0)
Basque country 749 (343.3) 187 (85.7) 1360 (623.4) 0 (0)
Canary Islandsb 1268 (597.4) 132 (62.2) 1036 (488.1) 1 (0.5)
Cantabriaa 190 (320.6) 40 (67.5) 304 (512.9) 0 (0)
Castile and Leóna 1100 (429.9) 162 (63.3) 1325 (517.8) 22 (8.6)
Castile-La Manchaa 857 (406.8) 95 (45.1) 1074 (509.8) 9 (4.3)
Cataloniab 3970 (528.5) 357 (47.5) 4601 (612.5) 0 (0)
Extremadurab 560 (505.3) 65 (58.6) 482 (434.9) 0 (0)
Galiciab 1445 (516.7) 278 (99.4) 1437 (513.8) 0 (0)
Valencian region 3214 (628.8) 241 (47.1) 2323 (454.4) 0 (0)
Sweden 2930 (312.4) 848 (90.4) 4746 (506.1) 1 (0.1)
The Netherlands 5222 (314.3) 1135 (68.3) 9025 (543.2) 1 (0.1)
UK, All countriesa,b 22 970 (368.9) 3960 (63.6) 23 235 (373.2) 922 (14.8)
Englanda,b 19 215 (367.9) 3392 (64.9) 19 166 (366.9) 902 (17.3)
Northern Irelanda,b 744 (413.4) 69 (38.3) 680 (377.8) 1 (0.6)
Scotland 1909 (365.5) 292 (55.9) 2225 (426.1) 8 (1.5)
Walesa,b 1113 (370.2) 218 (72.5) 1236 (411.1) 11 (3.7)
All countries 120 114 (469.7) 15 777 (61.7) 102 857 (402.2) 1341 (5.2)
Regions providing aggregated data
Bosnia and Herzegovina 2305 (657.1) 111 (31.6) 166 (47.3) 9 (2.6)
Croatia 2692 (606.7) 234 (52.7) 1250 (281.7) 0 (0)
Czech Republic 5820 (552.5) 498 (47.3) 3900 (370.3) 0 (0)
Estonia 237 (176.9) 76 (56.7) 398 (297.0) 0 (0)
France (23 of 26 regions) 34 850 (550.8) 2579 (40.8) 29 841 (471.6) 0 (0)
FYR of Macedonia 1312 (648.9) 26 (12.9) 140 (69.2) 0 (0)
Israelb 5175 (678.9) 341 (44.7) 0 (0)
Italy (14 of 20 regions)b 28 861 (751.1) 2535 (66.0) 3413 (88.8)
Latvia 414 (185.7) 110 (49.3) 458 (205.5) 0 (0)
Montenegro 112 (180.6) 13 (21.0) 81 (130.6) 0 (0)
Poland 17 193 (474.7) 1099 (30.3) 8042 (222.0) 0 (0)
Portugal 10 152 (955.3) 660 (62.1) 5976 (562.3) 0 (0)
Russia 18 722 (131.9) 1757 (12.4) 5848 (41.2) 0 (0)
Serbia 4081 (542.1) 468 (62.2) 997 (132.4) 0 (0)
Slovakiab 2918 (553.4) 102 (19.3) 0 (0)
Spain (18 of 19 regions) 21 680 (475.8) 2410 (52.9) 23 140 (507.9) 0 (0)
Turkey 41 296 (671.5) 4393 (71.4) 6422 (104.4) 0 (0)
Ukraine 4181 (92.2) 650 (14.3) 772 (17.0) 0 (0)
All countries 202 001 (414.0) 18 062 (37.0) 87 431 (200.2) 3422 (7.0)
HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; Unkn/Miss, unknown/missing.
aPatients <20 years of age are not reported.
bData include dialysis patients only.
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Appendix
Statistical methods
Table 8 presents data on the survival of incident patients
on RRT and of patients receiving a ﬁrst transplant
between 2001 and 2005 or between 2004 and 2008 with
95% CIs. Patients were followed until 31 December 2010.
Statistical analysis of unadjusted survival was performed
by the Kaplan–Meier method, while for the adjusted sur-
vival analyses the Cox regression model was used.
For the analysis of patient survival on RRT, the day of
the start of RRT was taken as the starting point and the
event studied was death. Censored observations were re-
covery of renal function, loss to follow-up and end of
follow-up time. Regarding the analysis of patient survival
on dialysis, the ﬁrst day on dialysis was the starting point,
the event was death and reasons for censoring were re-
covery of renal function, loss to follow-up, end of follow-
up time and renal transplantation. In the Cox regression
model, we adjusted for ﬁxed values of age (60 years),
gender (60% men) and PRD (20% diabetes mellitus, 17%
hypertension/renal vascular disease, 15% glomerulone-
phritis and 48% other causes).
For the analysis of patient and graft survival after
transplantation, the date of the ﬁrst renal transplantation
was deﬁned as the ﬁrst day of follow-up. The event
studied for the patient survival after transplantation was
death, while for the graft survival the events were graft
failure and death. The reasons for censoring were loss to
follow-up and end of follow-up time. In the adjusted ana-
lyses, we adjusted for ﬁxed values of age (45 years),
gender (60% men) and PRD (10% diabetes mellitus, 8%
hypertension/renal vascular disease, 28% glomerulone-
phritis and 54% other causes). Patients for whom age,
gender or PRD was missing were excluded.
Afﬁliated registries
Belgium, Dutch-speaking: B. De Moor and H. Augustijn;
Belgium, French-speaking: J.M. des Grottes; Bosnia-
Fig. 4. Renal transplants performed pmp in 2010, by donor type, unadjusted. Figures include data from renal registries providing individual patient data
(left ﬁgure) and aggregated data (right ﬁgure). For Romania, the transplantation activity reﬂects 70% of the total transplantation activity in the country,
because there is an under-reporting of pre-emptive transplantations. We used data from NHS Blood and Transplant Service, Centro Nazionale Trapianti,
the Slovak Centre of Organ Transplantation and the Organización Nacional de Trasplantes (ONT) for UK, Italy (14 of 20 regions), Slovakia and Spain (18
of 19 regions), respectively.
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Herzegovina: E. Mešić and B. Prnjavorac; Croatia: Croatian
Registry for RRT, Croatian Regional Registries for RRT and
Croatian Society for Nephrology, Dialysis and Transplan-
tation; Czech Republic: I. Rychlík and J. Potucek; Estonia:
Ü. Pechter and M. Luman; Finland: C. Grönhagen-Riska;
France: M. Lassalle; Israel: R. Dichtiar and T. Shohat; Italy:
A. Rustici, M. Nichelatti, A. Molino, M. Salomone, G. Cappelli,
F. Antonucci, A. Santoro, E. Mancini, M. Standoli, M.
Bonomini, L. DiLiberato, A. DiNapoli, F. Casino, C. Zoccali,
A.M. Pinna and J.H. Levialdi Ghiron; Latvia: V. Kuzema; Mon-
tenegro: S. Ivanovic; Poland: G. Korejwo and P. Jagodziński;
Portugal: R. Filipe and F. Nolasco; Romania: G. Mircescu and
E. Podgoreanu; Russia: B.T. Bikbov; Serbia: Working group of
Serbian RRT Registry and all of the Serbian renal units; Slo-
vakia: I. Lajdova and M, Karolyova; Spain, Andalusia: M.A.
Pćrez Valdivia; Spain, Aragon: J.I. Sanchez Miret; Spain, As-
turias: J.R. Quiros; Spain, Basque country: J. Aranzabal, M.
Rodrigo and I. Moina; Spain, Canary Islands: V. Lorenzo
Table 9. Expected remaining lifetimes (years) of the general population in 2005, and of prevalent dialysis and transplant patients in 2009 and 2010
(includes mortality in the ﬁrst 90 days)a
General population Dialysis patients Transplant patients
Age All Men Women Age All Men Women Age All Men Women
0 79.4 76.7 81.9 0–19 36.5 37.9 34.4 0–19 61.4 61.0 62.1
5 74.8 72.2 77.3
10 69.8 67.2 72.3
15 64.9 62.2 67.4
20 60.0 57.4 62.4 20–24 19.9 20.6 18.9 20–24 43.5 42.8 44.9
25 55.1 52.6 57.5 25–29 17.1 17.5 16.4 25–29 39.2 38.5 40.4
30 50.3 47.8 52.6 30–34 14.6 14.8 14.2 30–34 35.1 34.3 36.4
35 45.4 43.0 47.7 35–39 12.4 12.5 12.3 35–39 31.0 30.2 32.5
40 40.6 38.3 42.9 40–44 10.7 10.6 10.7 40–44 27.0 26.2 28.3
45 35.9 33.6 38.1 45–49 9.2 9.2 9.3 45–49 23.1 22.4 24.5
50 31.3 29.1 33.4 50–54 7.8 7.7 7.9 50–54 19.7 19.0 20.8
55 26.9 24.7 28.8 55–59 6.7 6.6 6.9 55–59 16.4 15.8 17.3
60 22.6 20.6 24.4 60–64 5.6 5.5 5.8 60–64 13.4 13.0 14.0
65 18.6 16.7 20.1 65–69 4.9 4.8 5.1 65–69 10.4 10.1 10.9
70 14.8 13.1 16.1 70–74 4.2 4.1 4.3 70–74 7.8 7.7 8.1
75 11.3 10.0 12.3 75–79 3.4 3.4 3.5
80 8.4 7.4 9.0 80–84 2.5 2.5 2.5
85 6.2 5.5 6.5
aBased on the data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Italy (Calabria), Norway,
Spain (Andalusia), Spain (Asturias), Spain (Basque Country), Spain (Cantabria), Spain (Catalonia), Spain (Valencian region), Sweden, the Netherlands, UK
(England and Wales), UK (Scotland).
Table 8. The 1-, 2- and 5-year survival probabilities (95% CI) for patients who started RRT/dialysis or underwent renal transplantation between 2000
and 2004 and between 2004 and 2008
Cohort 2001–2005a Cohort 2004–2008b
1 year 2 year 5 year 1 year 2 year
Patient survival on RRT
Unadjusted 80.6 (80.4–80.8) 69.1 (68.9–69.3) 46.2 (46.0–46.3) 82.2 (82.0–82.4) 71.3 (71.1–71.5)
Adjustedc 87.7 (87.5–87.9) 79.0 (78.7–79.3) 57.1 (56.7–57.5) 88.7 (88.5–88.9) 80.7 (80.5–81.0)
Patient survival on dialysis
Unadjusted 79.9 (79.7–80.1) 67.1 (66.8–67.3) 38.6 (38.5–38.8) 81.3 (81.1–81.5) 69.2 (69.0–69.4)
Adjustedc 85.9 (85.7–86.2) 76.0 (75.7–76.3) 50.3 (49.8–50.8) 87.5 (87.3–87.7) 78.5 (78.2–78.8)
Patient survival after ﬁrst transplant (deceased donor)
Unadjusted 95.5 (95.2–95.8) 93.4 (93.0–93.8) 86.6 (86.1–87.1) 95.9 (95.6–96.2) 94.0 (93.7–94.4)
Adjustedd 97.1 (96.9–97.4) 95.7 (95.4–96.0) 91.0 (90.5–91.5) 97.4 (97.1–97.6) 96.1 (95.8–96.4)
Patient survival after ﬁrst transplant (living donor)
Unadjusted 97.6 (97.0–98.0) 96.6 (96.0–97.1) 94.1 (93.4–94.8) 98.3 (97.9–98.6) 97.5 (97.0–97.9)
Adjustedd 97.7 (97.2–98.2) 96.8 (96.2–97.4) 94.2 (93.4–95.1) 98.5 (98.2–98.9) 97.8 (97.4–98.3)
Graft survival after ﬁrst transplant (deceased donor)
Unadjusted 89.6 (89.2–90.1) 86.6 (86.1–87.1) 76.9 (76.4–77.5) 90.2 (89.7–90.6) 87.4 (86.9–87.8)
Adjustedd 90.7 (90.2–91.2) 87.9 (87.4–88.5) 78.9 (78.2–79.7) 91.1 (90.7–91.6) 88.6 (88.1–89.1)
Graft survival after ﬁrst transplant (living donor)
Unadjusted 93.8 (93.0–94.4) 91.8 (91.0–92.6) 85.9 (84.9–86.8) 94.8 (94.2–95.3) 92.9 (92.2–93.5)
Adjustedd 93.5 (92.7–94.3) 91.4 (90.5–92.4) 85.2 (83.9–86.4) 94.4 (93.8–95.1) 92.5 (91.7–93.2)
aBased on the data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Italy (Calabria), Norway,
Spain (Andalusia), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Catalonia), Spain (Valencian region), Sweden, the Netherlands, UK
(England and Wales) and UK (Scotland).
bBased on the data from Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, Greece, Iceland, Italy (Calabria), Norway,
Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain
(Catalonia), Spain (Extremadura), Spain (Valencian region), Sweden, the Netherlands, UK (England and Wales) and UK (Scotland).
cAnalyses were adjusted using ﬁxed values: age (60 years), gender (60% men) and PRD (20% diabetes mellitus, 17% hypertension/renal vascular
disease, 15% glomerulonephritis and 48% other causes).
dAnalyses were adjusted using ﬁxed values: age (45 years), gender (60% men) and PRD (10% diabetes mellitus, 8% hypertension/renal vascular
disease, 28% glomerulonephritis and 54% other causes).
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Sellarés and N. Vega Díaz; Spain, Cantabria: M. Arias; Spain,
Castile and León: C. García-Renedo; Spain, Castile-La
Mancha: G. Gutiérrez Ávila and I. Moreno Alía; Spain, Cata-
lonia: E. Arcos, J. Comas and P. A. Montserrat; Spain, Extre-
madura: J.M. Ramos Aceitero; Spain, Galicia: J. Sánchez-
Ibáñez; Spain, Valencian region: O. Zurriaga Llorens; Spain
(18 of 19 regions): Spanish RRT National Registry at ONT,
Spanish Regional Registries and Spanish Society of Nephrol-
ogy; Sweden: L. Bäckman, M. Evans, S. Schön, M. Stendahl
and B. Rippe; The Netherlands: A. Hemke; Turkey: G. Süley-
manlar; Ukraine: G. Vladzievska and M. Kulyzkyi; UK,
England/Northern Ireland/Wales: All the staff of the UK
Renal Registry and of the renal units submitting data; UK,
Scotland: The staff of the Scottish Renal Registry and all of
the Scottish renal units.
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Germany (Chairman); D. Ansell, UK; C. Combe, France;
L. Garneata, Romania; F. Jarraya, Tunisia; P. Ravani, Italy;
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